Asahi shares mark weekly slide after cyberattack halts production
Patrick R. O’Neil, Executive Vice President, CLO & General Counsel at Ionis Pharmaceuticals (NASDAQ:IONS), sold 25,299 shares of common stock on September 29 and 30, 2025. The sales were executed at weighted average prices ranging from $64.5417 to $64.6777, resulting in a total transaction value of approximately $1.6 million.
The transactions were executed under a Rule 10b5-1 trading plan adopted on May 2, 2025.
On the same dates, O’Neil also exercised options to acquire a total of 25,299 shares of Ionis Pharmaceuticals common stock at a price of $56.78 per share, for a total value of $1436534.
In other recent news, Ionis Pharmaceuticals has reported significant developments in its clinical trials and analyst evaluations. Positive Phase 3 trial results for zilganersen, a treatment for the rare neurological condition Alexander disease, have been highlighted by several analyst firms. H.C. Wainwright reiterated its Buy rating with a $95.00 price target, noting the drug’s potential disease-modifying benefits. Guggenheim also raised its price target to $92.00, maintaining a Buy rating due to the promising trial data. Additionally, Leerink Partners increased its price target to $68.00, citing the strong topline results for zilganersen. In another development, Goldman Sachs upgraded Ionis Pharmaceuticals from Sell to Neutral, setting a price target of $65.00. This upgrade was based on the potential of Ionis’ antisense oligonucleotide technology, particularly following positive data for Tryngolza in severe hypertriglyceridemia. These recent advancements underscore Ionis Pharmaceuticals’ ongoing progress in its drug development pipeline.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.